Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 25350695.
- Also identified by DOI 10.1038/ncomms6068 and PMC identifier 4220464.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Statins effectively lower LDL cholesterol levels in large studies and the observed interindividual response variability may be partially explained by genetic variation. Here we perform a pharmacogenetic meta-analysis of genome-wide association studies (GWAS) in studies addressing the LDL cholesterol response to statins, including up to 18,596 statin-treated subjects. We validate the most promising signals in a further 22,318 statin recipients and identify two loci, SORT1/CELSR2/PSRC1 and SLCO1B1, not previously identified in GWAS. Moreover, we confirm the previously described associations with APOE and LPA. Our findings advance the understanding of the pharmacogenetic architecture of statin response.
Medical subject headings
- Cholesterol, LDL
- Genome-Wide Association Study
- Hydroxymethylglutaryl-CoA Reductase Inhibitors